Huaren Pharmaceutical: The application for the listing of isoproterenol hydrochloride chemical raw materials has been approved
I'm PortAI, I can summarize articles.
Huaren Pharmaceutical's wholly-owned subsidiary Anhui Hengxing Pharmaceutical has received approval from the National Medical Products Administration for the market launch application of isoproterenol hydrochloride chemical raw materials. This drug is a non-selective β-adrenergic agonist, primarily used to treat cardiogenic or infectious shock, atrioventricular conduction block, cardiac arrest, and acute bronchial asthma attacks
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments